SCHEMBL101545

SCHEMBL101545

[CH2]C(CCC)CCC(C)C

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10347243 0.87 TSHR (0.40) TSHR
SCHEMBL42248 0.84
SCHEMBL10611346 0.83 DNM1 (0.36) TSHR
SCHEMBL10347443 0.79 OPRM1 (0.42) TSHR
SCHEMBL3884688 0.79
SCHEMBL1447644 0.77 LMNA (0.48)
SCHEMBL7010805 0.77
SCHEMBL28617833 0.74 LMNA (0.32) TSHR
SCHEMBL4134630 0.74
Ethylene SCHEMBL28232721 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4265595-A1 SULFONATE COMPOSITION PRODUCTION METHOD Kao Corporation (JP) 2023-10-25 EP claimed
EP-4265596-A1 SULFONATE COMPOSITION Kao Corporation (JP) 2023-10-25 EP claimed
US-20230331666-A1 METHOD FOR PRODUCING SULFONATE COMPOSITION KAO CORPORATION (JP) 2023-10-19 US claimed
CN-116568670-A Method for producing sulfonate composition 花王株式会社 2023-08-08 CN claimed
CN-116406354-A Sulfonate composition 花王株式会社 2023-07-07 CN claimed
CN-103068786-B Cosmetic preparation COGNIS IP MANAGEMENT GMBH (DE) 2016-01-20 CN claimed
US-8940943-B2 Cosmetic preparations COGNIS IP MANAGEMENT GMBH (DE) 2015-01-27 US claimed
EP-2601166-A1 COSMETIC PREPARATIONS Cognis IP Management GmbH (DE) 2013-06-12 EP claimed
US-20130131188-A1 Cosmetic Preparations COGNIS IP MANAGEMENT GMBH (DE) 2013-05-23 US claimed
CN-103068786-A Cosmetic preparation COGNIS IP MAN GMBH 2013-04-24 CN claimed
EP-2426101-A1 Cosmetic preparations Cognis IP Management GmbH (DE) 2012-03-07 EP claimed
WO-2012016642-A1 COSMETIC PREPARATIONS COGNIS IP MANAGEMENT GMBH (DE) 2012-02-09 WO claimed
EP-4365287-A1 METHOD FOR PROMOTING ENZYMATIC REACTION Kao Corporation (JP) 2024-05-08 EP disclosed
CN-117377758-A Enzymatic reaction promotion method 花王株式会社 2024-01-09 CN disclosed
EP-4265595-A1 SULFONATE COMPOSITION PRODUCTION METHOD Kao Corporation (JP) 2023-10-25 EP disclosed
EP-4265596-A1 SULFONATE COMPOSITION Kao Corporation (JP) 2023-10-25 EP disclosed
EP-2268764-A1 USE OF TENSIDE MIXTURES FOR TERTIARY OIL PRODUCTION BASF SE (DE) 2011-01-05 EP disclosed
WO-2009130141-A1 USE OF TENSIDE MIXTURES FOR TERTIARY OIL PRODUCTION BASF SE (DE) 2009-10-29 WO disclosed
US-20090270281-A1 USE OF SURFACTANT MIXTURES FOR TERTIARY MINERAL OIL EXTRACTION BASF SE (DE) 2009-10-29 US disclosed
EP-1591466-A1 Preparation of a polyether composition BASF AKTIENGESELLSCHAFT (DE) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131188-A1 Cosmetic Preparations CYP1B1, CBR1, ACOX3 TSHR 1074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.